Harvest Fund Management Co. Ltd lifted its stake in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 438.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,838 shares of the medical instruments supplier's stock after acquiring an additional 3,940 shares during the quarter. Harvest Fund Management Co. Ltd's holdings in Glaukos were worth $726,000 as of its most recent filing with the SEC.
A number of other hedge funds have also made changes to their positions in the stock. IFP Advisors Inc bought a new position in Glaukos in the 4th quarter worth $43,000. Asset Planning Inc acquired a new stake in shares of Glaukos in the fourth quarter valued at about $90,000. Picton Mahoney Asset Management bought a new position in shares of Glaukos in the fourth quarter worth about $125,000. SBI Securities Co. Ltd. bought a new position in shares of Glaukos in the fourth quarter worth about $153,000. Finally, Smartleaf Asset Management LLC lifted its position in shares of Glaukos by 275.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,100 shares of the medical instruments supplier's stock worth $164,000 after purchasing an additional 807 shares during the last quarter. Institutional investors and hedge funds own 99.04% of the company's stock.
Insider Buying and Selling at Glaukos
In other news, insider Tomas Navratil sold 3,416 shares of the business's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the sale, the insider now owns 72,437 shares in the company, valued at approximately $10,658,380.18. The trade was a 4.50 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 6.40% of the company's stock.
Wall Street Analyst Weigh In
Several brokerages have commented on GKOS. Wells Fargo & Company lifted their price target on Glaukos from $153.00 to $160.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. Mizuho upgraded shares of Glaukos from a "neutral" rating to an "outperform" rating and raised their price objective for the stock from $140.00 to $200.00 in a research note on Wednesday, February 19th. UBS Group assumed coverage on shares of Glaukos in a research note on Friday, December 6th. They set a "buy" rating and a $182.00 target price for the company. Stephens upgraded shares of Glaukos to a "strong-buy" rating in a research report on Monday, December 2nd. Finally, BTIG Research boosted their price objective on shares of Glaukos from $140.00 to $149.00 and gave the stock a "buy" rating in a report on Tuesday, November 26th. One analyst has rated the stock with a sell rating, one has given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Glaukos currently has a consensus rating of "Moderate Buy" and a consensus price target of $163.25.
Read Our Latest Report on Glaukos
Glaukos Price Performance
NYSE GKOS traded down $0.89 on Tuesday, reaching $106.72. The company's stock had a trading volume of 526,460 shares, compared to its average volume of 586,428. Glaukos Co. has a 52 week low of $87.59 and a 52 week high of $163.71. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. The firm has a market cap of $6.04 billion, a PE ratio of -37.18 and a beta of 0.99. The business has a 50-day moving average price of $134.44 and a 200 day moving average price of $136.45.
Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The company had revenue of $105.50 million during the quarter, compared to the consensus estimate of $100.72 million. Sell-side analysts expect that Glaukos Co. will post -1.08 EPS for the current year.
Glaukos Profile
(
Free Report)
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
See Also
Before you consider Glaukos, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Glaukos wasn't on the list.
While Glaukos currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
